The Pro Allele of the p53 Codon 72 Polymorphism Is Associated with Decreased Intratumoral Expression of BAX and p21, and Increased Breast Cancer Risk

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Proestling, Katharina ^a   Hebar, Alexandra ^a   Pruckner, Nina ^a   Marton, Erika ^a   Vinatzer, Ursula ^a   Schreiber, Martin ^a  

^a UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; MESSENGER RNA; PROLINE; PROTEIN BAX; PROTEIN MDM2; PROTEIN P21; PROTEIN P53;

ADULT; ARTICLE; BAX GENE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CODON; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE; GENE EXPRESSION; GENE INACTIVATION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MDM2 GENE; ONSET AGE; OVERALL SURVIVAL; P21 GENE; PERP GENE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; BCL-2-ASSOCIATED X PROTEIN; BREAST NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; POLYMORPHISM, GENETIC; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; RISK FACTORS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84867383166     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047325     Document Type: Article

References (53)

1. Lacroix M, Toillon RA, Leclercq G, (2006) p53 and breast cancer, an update. Endocrine-related cancer 13: 293-325.
2. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825.
3. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, et al. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1501.
4. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ, (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816.
5. Fan Z, Shang BY, Lu Y, Chou JL, Mendelsohn J, (1997) Reciprocal changes in p27(Kip1) and p21(Cip1) in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors. Clinical cancer research 3: 1943-1948.
6. Dumble M, Gatza C, Tyner S, Venkatachalam S, Donehower LA, (2004) Insights into aging obtained from p53 mutant mouse models. Annals of the New York Academy of Sciences 1019: 171-177.
7. Attardi LD, Reczek EE, Cosmas C, Demicco EG, McCurrach ME, et al. (2000) PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. Genes & development 14: 704-718.
8. Jeong BS, Hu W, Belyi V, Rabadan R, Levine AJ, (2010) Differential levels of transcription of p53-regulated genes by the arginine/proline polymorphism: p53 with arginine at codon 72 favors apoptosis. FASEB journal 24: 1347-1353.
9. Dusek RL, Bascom JL, Vogel H, Baron S, Borowsky AD, et al. (2012) Deficiency of the p53/p63 target Perp alters mammary gland homeostasis and promotes cancer. Breast cancer research: BCR 14: R65.
10. Boyd SD, Tsai KY, Jacks T, (2000) An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nature cell biology 2: 563-568.
11. Geyer RK, Yu ZK, Maki CG, (2000) The MDM2 RING-finger domain is required to promote p53 nuclear export. Nature cell biology 2: 569-573.
12. Roth J, Dobbelstein M, Freedman DA, Shenk T, Levine AJ, (1998) Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. The EMBO journal 17: 554-564.
13. Tao W, Levine AJ, (1999) Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proceedings of the National Academy of Sciences of the United States of America 96: 3077-3080.
14. Vassilev LT, (2007) MDM2 inhibitors for cancer therapy. Trends in molecular medicine 13: 23-31.
15. Wu X, Bayle JH, Olson D, Levine AJ, (1993) The p53-mdm-2 autoregulatory feedback loop. Genes & development 7: 1126-1132.
16. Olivier M, Hussain SP, Caron de Fromentel C, Hainaut P, Harris CC (2004) TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC scientific publications: 247-270.
17. Vousden KH, Lu X, (2002) Live or let die: the cell's response to p53. Nature reviews Cancer 2: 594-604.
18. Norberg T, Klaar S, Karf G, Nordgren H, Holmberg L, et al. (2001) Increased p53 mutation frequency during tumor progression-results from a breast cancer cohort. Cancer research 61: 8317-8321.
19. Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, et al. (2006) The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clinical cancer research 12: 1157-1167.
20. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, et al. (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Human mutation 28: 622-629.
21. Dumont P, Leu JI, Della Pietra AC, 3rd, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nature genetics 33: 357-365.
22. Pim D, Banks L, (2004) p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. International journal of cancer 108: 196-199.
23. Siddique M, Sabapathy K, (2006) Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene 25: 3489-3500.
24. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, et al. (1998) Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393: 229-234.
25. Su L, Sai Y, Fan R, Thurston SW, Miller DP, et al. (2003) P53 (codon 72) and P21 (codon 31) polymorphisms alter in vivo mRNA expression of p21. Lung cancer 40: 259-266.
26. Sullivan A, Syed N, Gasco M, Bergamaschi D, Trigiante G, et al. (2004) Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 23: 3328-3337.
27. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, et al. (1999) Two polymorphic variants of wild-type p53 differ biochemically and biologically. Molecular and cellular biology 19: 1092-1100.
28. Huang XE, Hamajima N, Katsuda N, Matsuo K, Hirose K, et al. (2003) Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer 10: 307-311.
29. Sjalander A, Birgander R, Hallmans G, Cajander S, Lenner P, et al. (1996) p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 17: 1313-1316.
30. Ohayon T, Gershoni-Baruch R, Papa MZ, Distelman Menachem T, Eisenberg Barzilai S, et al. (2005) The R72P P53 mutation is associated with familial breast cancer in Jewish women. Br J Cancer 92: 1144-1148.
31. Zhang Z, Wang M, Wu D, Tong N, Tian Y, (2010) P53 codon 72 polymorphism contributes to breast cancer risk: a meta-analysis based on 39 case-control studies. Breast cancer research and treatment 120: 509-517.
32. Buyru N, Tigli H, Dalay N, (2003) P53 codon 72 polymorphism in breast cancer. Oncol Rep 10: 711-714.
33. Baynes C, Healey CS, Pooley KA, Scollen S, Luben RN, et al. (2007) Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk. Breast Cancer Res 9: R27.
34. The Breast Cancer Association Consortium, (2006) Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. Journal of the National Cancer Institute 98: 1382-1396.
35. Tommiska J, Eerola H, Heinonen M, Salonen L, Kaare M, et al. (2005) Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 11: 5098-5103.
36. He XF, Su J, Zhang Y, Huang X, Liu Y, et al. (2011) Association between the p53 polymorphisms and breast cancer risk: meta-analysis based on case-control study. Breast cancer research and treatment 130: 517-529.
37. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, et al. (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447: 1087-1093.
38. Turnbull C, Ahmed S, Morrison J, Pernet D, Renwick A, et al. (2010) Genome-wide association study identifies five new breast cancer susceptibility loci. Nature genetics 42: 504-507.
39. Hu Z, Li X, Yuan R, Ring BZ, Su L, (2010) Three common TP53 polymorphisms in susceptibility to breast cancer, evidence from meta-analysis. Breast cancer research and treatment 120: 705-714.
40. Ma Y, Yang J, Liu Z, Zhang P, Yang Z, et al. (2011) No significant association between the TP53 codon 72 polymorphism and breast cancer risk: a meta-analysis of 21 studies involving 24,063 subjects. Breast cancer research and treatment 125: 201-205.
41. Schmidt MK, Reincke S, Broeks A, Braaf LM, Hogervorst FB, et al. (2007) Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. Cancer Res 67: 9584-9590.
42. Pietsch EC, Humbey O, Murphy ME, (2006) Polymorphisms in the p53 pathway. Oncogene 25: 1602-1611.
43. Sucheston L, Witonsky DB, Hastings D, Yildiz O, Clark VJ, et al. (2011) Natural selection and functional genetic variation in the p53 pathway. Human molecular genetics 20: 1502-1508.
44. Schmidt MK, Tommiska J, Broeks A, van Leeuwen FE, Van't Veer LJ, et al. (2009) Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients. Breast cancer research 11: R89.
45. Xu Y, Yao L, Ouyang T, Li J, Wang T, et al. (2005) p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res 11: 7328-7333.
46. Vinatzer U, Dampier B, Streubel B, Pacher M, Seewald MJ, et al. (2005) Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization. Clinical cancer research 11: 8348-8357.
47. R Development Core Team (2009) R: A language and environment for statistical computing. In R Foundation for Statistical Computing, Vienna, Austria.
48. Bender R, Lange S, (2001) Adjusting for multiple testing-when and how? Journal of clinical epidemiology 54: 343-349.
49. Harrington DP, Fleming TR, (1982) A Class of Rank Test Procedures for Censored Survival-Data. Biometrika 69: 553-566.
50. De Vecchi G, Verderio P, Pizzamiglio S, Manoukian S, Bernard L, et al. (2008) The p53 Arg72Pro and Ins16bp polymorphisms and their haplotypes are not associated with breast cancer risk in BRCA-mutation negative familial cases. Cancer detection and prevention 32: 140-143.
51. Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, et al. (2006) Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. Journal of medical genetics 43: 531-533.
52. Langerod A, Bukholm IR, Bregard A, Lonning PE, Andersen TI, et al. (2002) The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer epidemiology, biomarkers & prevention: 1684-1688.
53. Norberg T, Lennerstrand J, Inganas M, Bergh J, (1998) Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection of p53 gene mutations using cDNA sequencing in human breast tumors. Int J Cancer 79: 376-383.